SuperworthAlnylam Pharmaceuticals ALNY
- Market cap
- $30B
- PE
- 37.8×
- Forward PE
- 26.7×
- 10y median 64.4×
- Price to sales
- 6.2×
- EV/EBIT
- 27.9×
- Revenue, 12 months
- $4.8B
- +95% on a year ago
- Net margin
- 16.8%
- Free cash flow yield
- 2.6%
Alnylam Pharmaceuticals trades at 37.8× trailing earnings. Revenue was $4.8B over the last twelve months, up 95% on a year earlier with a 17% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $750.5M+184% | $439.7M+31% | $494.3M+55% | $659.8M+107% | $500.9M−33% | $593.2M+35% | $594.2M+20% | $773.7M+17% | $1.2B+149% | $1.1B+85% | $1.2B+96% | $1.3B+67% | |
| Cost of revenue | $84.3M+105% | $85.9M+68% | $66M+20% | $68.7M−20% | $85.9M+2% | $102.8M+20% | $71M+8% | $143M+108% | $200.2M+133% | $267.7M+160% | $211.1M+197% | $298.5M+109% |
| Gross profit | $666.2M+199% | $353.9M+25% | $428.4M+62% | $591.2M+153% | $415M−38% | $490.3M+39% | $523.1M+22% | $630.7M+7% | $1B+153% | $829.3M+69% | $956.1M+83% | $992.5M+57% |
| R&D | $253.2M+3% | $272.1M+4% | $261M+13% | $294.1M+18% | $270.9M+7% | $300.2M+10% | $265.1M+2% | $323.6M+10% | $358.8M+32% | $372.2M+24% | $364.9M+38% | $413.1M+28% |
| SG&A | $199.2M−16% | $198.1M−6% | $210.8M+15% | $248.4M+16% | $221M+11% | $295.3M+49% | $239.9M+14% | $323.3M+30% | $322.1M+46% | $325.4M+10% | $322.6M+34% | $347.9M+8% |
| $213.9M | −$116.4M−38% | −$43.4M−71% | $48.6M | −$76.9M | −$105.2M−10% | $18.1M | −$16.2M | $368M | $131.7M | $268.6M+1386% | $231.4M | |
| Interest expense | $30.9M−25% | $31.3M+5% | $35.3M+22% | $33.3M+11% | $34.4M+11% | $39M+24% | $58.3M+65% | $61.5M+85% | $44.4M+29% | $129.3M+232% | $69.3M+19% | $82.1M+34% |
| Pre-tax income | $150.7M | −$137.7M−34% | −$63.6M−63% | −$11.2M−96% | −$108.7M | −$194M+41% | −$2.4M−96% | −$41.3M+270% | $239M | $161.1M | $221.7M | $177.8M |
| $3M | $183K−61% | $2.3M+35% | $5.7M+215% | $2.9M−3% | −$110.2M | $15.9M+576% | $30.9M+440% | −$12.1M | −$25.3M−77% | $15.7M−1% | $13.3M−57% | |
| Net income | $147.8M | −$137.9M−34% | −$65.9M−62% | −$16.9M−94% | −$111.6M | −$83.8M−39% | −$18.3M−72% | −$72.2M+328% | $251.1M | $186.4M | $206M | $164.5M |
| $1.15 | −$1.10−35% | −$0.52−63% | −$0.13−94% | −$0.87 | −$0.65−41% | −$0.14−73% | −$0.55+323% | $1.84 | $1.37 | $1.51 | $1.21 | |
| 131.3M+8% | 125.6M+2% | 126.1M+2% | 126.7M+2% | 128.6M−2% | 129.1M+3% | 129.7M+3% | 130.6M+3% | 137.3M+7% | 136.3M+6% | 138.2M+7% | 138.3M+6% |
Gross profit: 32 periods, Q3 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY09 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $1.4B | $1.4B to $1.5B | $1.67 | $1.54 to $1.81 | 10 |
| Q4 FY26 | $1.6B | $1.5B to $1.7B | $2.05 | $1.67 to $2.44 | 9 |
| Q1 FY27 | $1.6B | $1.5B to $1.7B | $2.04 | $1.90 to $2.22 | 6 |
| Q2 FY27 | $1.7B | $1.6B to $1.8B | $2.18 | $2.03 to $2.37 | 3 |
| Q3 FY27 | $1.8B | $1.7B to $1.9B | $2.43 | $2.27 to $2.65 | 3 |
| Q4 FY27 | $1.9B | $1.8B to $2.1B | $3.05 | $2.84 to $3.32 | 6 |
| Q1 FY28 | $1.8B | $1.7B to $2B | $2.36 | $2.20 to $2.57 | 8 |
| Q2 FY28 | $1.9B | $1.8B to $2B | $2.30 | $2.15 to $2.51 | 4 |
Peers
Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| REGNRegeneron Pharmaceuticals | $82.9B | 19.9× | 19.7× | 12.6× | 5.3× | +9% | 27.9% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| Peer median | $15.2B | 29.3× | 39.8× | 35.1× | 7.5× | +20% | 26.3% |
Investors who own it
Investors we follow who held Alnylam Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.7% of portfoliotrimmed
More on Alnylam Pharmaceuticals
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 53Healthcare stocks with the fastest expected revenue growth
- #3of 34Healthcare stocks with the lowest PEG ratio
- #7of 36Biotech stocks with the fastest revenue growth
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .